Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs will be updated July 1, 2021:

Effective August 1, 2021:

• Acute Migraine Agents
• Alpha-1 Proteinase Inhibitors
• Antidepressant Agents
• Cannabidiol
• Coagulation Factor X
• Galafold (migalastat)
• Hetlioz (Previously Circadian Rhythm Disorder)
• Jynarque
• Lysosomal Storage Disorders
• Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) Inhibitors
• Peanut Allergy
• Substrate Reduction Therapy

If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant. 
Institutional Providers
Professional Providers